表紙
市場調查報告書

A型血友病:開發中產品分析

Hemophilia A - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232826
出版日期 內容資訊 英文 212 Pages
訂單完成後即時交付
價格
Back to Top
A型血友病:開發中產品分析 Hemophilia A - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 212 Pages
簡介

A型血友病是患者缺乏第八凝血因子(F8),而無法凝血所引發的疾病,會由於遺傳或突變產生。配合第八凝血因子的運作水準,血友病患者容易瘀血,受傷也難以止血,嚴重的血友病患者甚至會伴隨自發性出血。症狀有伴隨疼痛及腫大的關節內出血及血尿、血便、瘀傷、消化道與尿道的出血、鼻血、割傷及拔牙、手術後出血不止、突發性出血等。

本報告提供A型血友病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

血友病 A 概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Apitope International NV
  • Bayer AG
  • BioMarin Pharmaceutical Inc
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • Chugai Pharmaceutical Co Ltd
  • CSL Ltd
  • DBV Technologies SA
  • Dimension Therapeutics Inc
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Expression Therapeutics LLC
  • Green Cross Corp
  • Idogen AB
  • Immusoft Corp
  • Lentigen Technology Inc
  • mAbxience SA
  • Novo Nordisk A/S
  • OPKO Biologics Ltd
  • Pangen Biotech Inc.
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • rEVO Biologics Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • SK Chemicals Co Ltd
  • Spark Therapeutics Inc
  • UniQure NV
  • XL-protein GmbH

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11798IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides an overview of the Hemophilia A (Hematology ) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematology ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematology ) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A (Factor VIII Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 16, 8, 3, 1, 29, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Hemophilia A (Hematology ) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematology ).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematology ) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia A (Hematology ) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia A (Hematology ) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematology )

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematology ).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematology ) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia A (Factor VIII Deficiency) - Overview
    • Hemophilia A (Factor VIII Deficiency) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hemophilia A (Factor VIII Deficiency) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hemophilia A (Factor VIII Deficiency) - Companies Involved in Therapeutics Development
    • Alveron Pharma
    • ApcinteX Ltd
    • Apitope International NV
    • ASC Therapeutics Inc
    • Ascension Healthcare Plc
    • Beijing Northland Biotech Co Ltd
    • Beijing Tiantan Biological Products Co Ltd
    • BioMarin Pharmaceutical Inc
    • Cabaletta Bio Inc
    • Casebia Therapeutics
    • Catalyst Biosciences Inc
    • Chugai Pharmaceutical Co Ltd
    • CSL Ltd
    • Daiichi Sankyo Co Ltd
    • DBV Technologies SA
    • Dnarx LLC
    • EpiVax Inc
    • Expression Therapeutics LLC
    • Freeline Therapeutics Ltd
    • GC Pharma
    • Generation Bio Corp
    • Genzyme Corp
    • ID Pharma Co Ltd
    • Idogen AB
    • Immusoft Corp
    • Innovare R & D SA De CV
    • Kaifeng Pharmaceutical (Group) Co Ltd
    • Kymab Ltd
    • LambdaGen Therapeutics
    • LFB SA
    • NovalGen Ltd
    • Novo Nordisk AS
    • Octapharma AG
    • OPKO Biologics Ltd
    • Pangen Biotech Inc
    • Pfizer Inc
    • Pharming Group NV
    • Precision Biosciences Inc
    • ProFactor Pharma Ltd
    • Recursion Pharmaceuticals Inc
    • Sangamo Therapeutics Inc
    • Sanofi
    • Serpinx BV
    • Shenzhen Weiwu Guangming Biological Preparations Co Ltd
    • Sigilon Therapeutics Inc
    • Sino Biopharmaceutical Ltd
    • Sinocelltech Ltd
    • Spark Therapeutics Inc
    • Takeda Pharmaceutical Co Ltd
    • TeraImmune Inc
    • Ultragenyx Pharmaceutical Inc
    • UniQure NV
    • XL-protein GmbH
  • Hemophilia A (Factor VIII Deficiency) - Drug Profiles
  • Hemophilia A - Dormant Projects
  • Hemophilia A - Discontinued Products
  • Hemophilia A - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Pipeline by Alveron Pharma, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Pipeline by ApcinteX Ltd, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Pipeline by Apitope International NV, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Pipeline by ASC Therapeutics Inc, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Pipeline by Ascension Healthcare Plc, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Hemophilia A (Factor VIII Deficiency) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top